Rationale for Probiotic and Antibiotic Treatment Strategies in Inflammatory Bowel Diseases

2003 ◽  
Vol 21 (2) ◽  
pp. 105-128 ◽  
Author(s):  
Michael Schultz ◽  
Jürgen Schölmerich ◽  
Heiko C. Rath
Keyword(s):  
Antibiotic Treatment ◽  
Inflammatory Bowel Diseases ◽  
Treatment Strategies ◽  
Bowel Diseases ◽  
Inflammatory Bowel

Update on Imaging Modalities for Inflammatory Bowel Diseases

2016 ◽  
Author(s):  
Francesco Alessandrino ◽  
Koenraad J. Mortele
Keyword(s):  
Magnetic Resonance ◽  
Inflammatory Bowel Diseases ◽  
Treatment Strategies ◽  
Imaging Modalities ◽  
Dual Energy Ct ◽  
Multidetector Row Computed Tomography ◽  
Imaging Method ◽  
Pet Ct ◽  
Bowel Diseases ◽  
Inflammatory Bowel

Inflammatory bowel diseases (IBDs) are a group of chronic inflammatory disorders that are mainly represented by Crohn disease and ulcerative colitis. Over the last decade, conventional fluoroscopic barium studies used for the imaging of the gastrointestinal tract have been replaced with newer techniques, such as multidetector-row computed tomography (CT), dual-energy CT, and positron emission tomography (PET)/CT. Also increasingly seen is the use of magnetic resonance enterography, representing a robust, highly accurate, and radiation-free imaging method. This review covers these newer imaging modalities for IBD and more, as well as proposed techniques that could potentially help monitor and guide new antiinflammatory treatment strategies in the future. Figures include examples of images conducted via CT, magnetic resonance imaging, and PET/CT. Table compares different imaging modalities for the evaluation of IBD. This review contains 13 highly rendered figures, 1 table, and 127 references. 

Pediatric Inflammatory Bowel Diseases and the Risk of Lymphoma: Should We Revise Our Treatment Strategies?

2009 ◽  
Vol 48 (3) ◽  
pp. 257-267 ◽  
Author(s):  
Salvatore Cucchiara ◽  
Johanna C Escher ◽  
Hans Hildebrand ◽  
Jorge Amil-Dias ◽  
Laura Stronati ◽  
...  
Keyword(s):  
Inflammatory Bowel Diseases ◽  
Treatment Strategies ◽  
Bowel Diseases ◽  
Inflammatory Bowel

scholarly journals Precision medicine and inflammatory bowel diseases: concept, strategies, future

2021 ◽  
Vol 1 (6) ◽  
pp. 121-129
Author(s):  
G. R. Bikbavova ◽  
M. A. Livzan ◽  
D. G. Novikov ◽  
E. A. Bambulskaya
Keyword(s):  
Precision Medicine ◽  
Inflammatory Bowel Diseases ◽  
Scientific Information ◽  
Treatment Strategies ◽  
Wide Range ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
New Treatment ◽  
Personalized Approach ◽  
The Right

With the advent of modern cellular and genomic technologies, we have become participants in the integration of such areas as personalized, predictive, preventive, and precision medicine (referred to as 4P-medicine), into practical healthcare. In replace of the classic methods of diagnosis and treatment of diseases comes medicine, which makes it possible to predict (anticipate) the disease, and a personalized approach to each patient, taking into account their genetic, biochemical and physiological uniqueness. Precision medicine aims to improve the quality of medical care by opening up an individual approach to the patient and covers a wide range of areas, including drug therapy, genetics, and cause-and-effect relationships in order to make the right decisions based on evidence. 4P-medicine combines knowledge in the field of proteomics, metabolomics, genomics, bioinformatics with classical approaches of anatomy, therapy, laboratory and instrumental diagnostics as well as public health. The purpose of this review is to analyze and summarize the information available to date and to present examples of the application of modern approaches of medicine into clinical practice by diving into the example of inflammatory bowel diseases (IBD). The search for literature containing scientific information about relevant studies was conducted in the PubMed and Google Scholar systems with the use of the following keywords: precision medicine, 4P medicine, inflammatory bowel diseases. Despite significant progress in medicine in general, there is still a long way to go before implementing the principles of precision medicine in the field of IBD, since many clinicians continue to treat patients with IBD symptomatically. However, the use of specific biomarkers and new treatment strategies as described in the review, can significantly accelerate this path and contribute to the improvement of diagnostic and therapeutic approaches.

scholarly journals Biosimilar Interchangeability and Emerging Treatment Strategies for Inflammatory Bowel Diseases: A Commentary

2021 ◽  
Vol 12 (3) ◽  
pp. 293-301
Author(s):  
Richard H. Parrish
Keyword(s):  
Inflammatory Bowel Diseases ◽  
Treatment Strategies ◽  
Biologic Agent ◽  
Nocebo Effect ◽  
Treatment Access ◽  
Research Directions ◽  
The Us ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
Time Courses

This commentary summarizes a collection of key references published within the last ten years, and identifies pharmacologic research directions to improve treatment access and success through greater biosimilar or “follow-on” biologic utilization combined with other targeted small molecule agents that possess unique pathophysiologic mechanisms for inflammatory bowel diseases (IBD) in adult and pediatric patients. Since they are not identical to the originator or reference biologic agent, all biosimilars are not generically equivalent. However, in the US and other countries, they are considered therapeutically interchangeable if the manufacturer has demonstrated no clinically meaningful differences from the reference product. Comparisons of different clinical initiation and switching scenarios are discussed with reference to interchangeability, immunogenicity, nocebo effect, cost effectiveness, and time courses for discontinuation rates.

scholarly journals COVID-19 and Inflammatory Bowel Diseases: Risk Assessment, Shared Molecular Pathways, and Therapeutic Challenges

2020 ◽  
Vol 2020 ◽  
pp. 1-7
Author(s):  
Iolanda Valentina Popa ◽  
Mircea Diculescu ◽  
Cătălina Mihai ◽  
Cristina Cijevschi-Prelipcean ◽  
Alexandru Burlacu
Keyword(s):  
Inflammatory Bowel Diseases ◽  
Current Knowledge ◽  
Treatment Strategies ◽  
Translation Initiation Factor ◽  
Initiation Factor ◽  
Molecular Pathways ◽  
Beneficial Effects ◽  
Increased Risk ◽  
Bowel Diseases ◽  
Inflammatory Bowel

Background. The novel coronavirus SARS-CoV-2 causing COVID-19 disease is yielding a global outbreak with severe threats to public health. In this paper, we aimed at reviewing the current knowledge about COVID-19 infectious risk status in inflammatory bowel disease (IBD) patients requiring immunosuppressive medication. We also focused on several molecular insights that could explain why IBD patients appear not to have higher risks of infection and worse outcomes in COVID-19 than the general population in an attempt to provide scientific support for safer decisions in IBD patient care. Methods. PubMed electronic database was interrogated for relevant articles involving data about common molecular pathways and shared treatment strategies between SARS-CoV-2, SARS-CoV-1, MERS-CoV, and inflammatory bowel diseases. Besides, Neural Covidex, an artificial intelligence tool, was used to answer queries about pathogenic coronaviruses and possible IBD interactions using the COVID-19 Open Research Dataset (CORD-19). Discussions. Few molecular and therapeutic interactions between IBD and pathogenic coronaviruses were explored. First, we showed how the activity of soluble angiotensin-converting enzyme 2, CD209L other receptors, and phosphorylated α subunit of eukaryotic translation initiation factor 2 might exert protective impact in IBD in case of coronavirus infection. Second, IBD medication was discussed in the context of possible beneficial effects on COVID-19 pathogeny, including “cytokine storm” prevention and treatment, immunomodulation, interferon signaling blocking, and viral endocytosis inhibition. Conclusions. Using the current understanding of SARS-CoV-2 as well as other pathogenic coronaviruses immunopathology, we showed why IBD patients should not be considered at an increased risk of infection or more severe outcomes. Whether our findings are entirely applicable to the pathogenesis, disease susceptibility, and treatment management of SARS-CoV-2 infection in IBD must be further explored.

scholarly journals COVID-19 and Inflammatory Bowel Diseases: risk assessment, shared molecular pathways and therapeutic challenges

2020 ◽  
Author(s):  
Iolanda Valentina Popa ◽  
Mircea Diculescu ◽  
Cătălina Mihai ◽  
Cristina Cijevschi-Prelipcean ◽  
Alexandru Burlacu
Keyword(s):  
Inflammatory Bowel Diseases ◽  
Current Knowledge ◽  
Treatment Strategies ◽  
Translation Initiation Factor ◽  
Initiation Factor ◽  
Molecular Pathways ◽  
Beneficial Effects ◽  
Increased Risk ◽  
Bowel Diseases ◽  
Inflammatory Bowel

AbstractBackgroundThe novel coronavirus SARS-CoV-2 causing COVID-19 disease is yielding a global outbreak with serious threats to public health. In this paper, we aimed to review the current knowledge about COVID-19 infectious risk status in inflammatory bowel disease (IBD) patients requiring immunosuppressive medication. Also, we focused on several molecular insights that could explain why IBD patients appear to not have higher risks of infection and worse outcome in COVID-19 than the general population, in attempt to provide scientific support for safer decisions in IBD patient care.MethodsPubMed electronic database was interogated for relevant articles involving data about common molecular pathways and shared treatment strategies between SARS-CoV-2, SARS-CoV-1, MERS-CoV and inflammatory bowel diseases. In addition, Neural Covidex, an artificial intelligence tool, was used to answer queries about pathogenic coronaviruses and possible IBD interactions using the COVID-19 Open Research Dataset (CORD-19).DiscussionsFew molecular and therapeutic interactions between IBD and pathogenic coronaviruses were explored. First, we showed how the activity of soluble angiotensin-converting enzyme 2, CD209L alternate receptor and phosphorylated α subunit of eukaryotic translation initiation factor 2 might exert protective impact in IBD in case of coronavirus infection. Second, IBD medication was discussed in the context of possible beneficial effects on COVID-19 pathogeny including “cytokine storm” prevention and treatment, immunomodulation, interferon signaling blocking, viral endocytosis inhibition.ConclusionsUsing current understanding of SARS-CoV-2 as well as other pathogenic coronaviruses immunopathology, we showed why IBD patients should not be considered at an increased risk of infection or more severe outcomes. Whether our findings are entirely applicable to the pathogenesis, disease susceptibility and treatment management of SARS-CoV-2 infection in IBD must be further explored.

Sign in / Sign up

Export Citation Format

Share Document